The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
Bingfeng Shi - One of the best experts on this subject based on the ideXlab platform.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
ChemInform, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:The regioselectivity of the acetoxycyclization of N-allylureas to furnish either imidazoles or oxazoles is controlled by choice of the transition-metal catalyst.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
Organic Letters, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:A catalyst-controlled vicinal amino- versus oxy-acetoxylation of alkenes with PhI(OAc)2 as the oxidant is described. The divergent synthesis of cyclic ureas and Isoureas was achieved in good yields under mild conditions employing ambident urea nucleophiles. Both terminal and internal alkenes are compatible with this reaction protocol.
Weihao Rao - One of the best experts on this subject based on the ideXlab platform.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
ChemInform, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:The regioselectivity of the acetoxycyclization of N-allylureas to furnish either imidazoles or oxazoles is controlled by choice of the transition-metal catalyst.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
Organic Letters, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:A catalyst-controlled vicinal amino- versus oxy-acetoxylation of alkenes with PhI(OAc)2 as the oxidant is described. The divergent synthesis of cyclic ureas and Isoureas was achieved in good yields under mild conditions employing ambident urea nucleophiles. Both terminal and internal alkenes are compatible with this reaction protocol.
Trapero Puig Ana - One of the best experts on this subject based on the ideXlab platform.
-
Nous ciclitols com a inhibidors de la glucocerebrosidasa. Aplicació al disseny de xaperones farmacològiques per al tractament de la malaltia de Gaucher
'Edicions de la Universitat de Barcelona', 2011Co-Authors: Trapero Puig AnaAbstract:[cat] Els malalts de Gaucher manquen de l’activitat normal de l’enzim lisosomal Glucocerebrosidasa (GCase), una β–glucosidasa que hidrolitza l’enllaç glicosídic entre la glucosa i la ceramida, i són incapaços de metabolitzar la Glucosilceramida, que s’acumula a l’interior dels lisosomes dels macròfags impedint que aquests funcionin correctament. La presència de mutacions en el gen precursor de la GCase provoca un plegament incorrecte de la proteïna en el recicle endoplasmàtic i impedeixen el seu transport al lisosoma on hidrolitza el substrat i, per tant, aquest últim s’acumula en els lisosomes. Per altra banda, la proteïna es degradada en el mateix reticle endoplasmàtic o en l’aparell de Golgi pels proteasomes. Els tractaments actuals per a aquesta malaltia es basen en la inhibició de la producció de substrat utilitzant inhibidors de l’enzim implicat en la seva biosíntesi o en l’augment de l’enzim mitjançant reemplaçament enzimàtic. Durant els últims anys s’han desenvolupat diverses estratègies terapèutiques per a la malaltia de Gaucher. Entre elles, una que ha despertat un gran interès consisteix en el disseny de xaperones farmacològiques, que són inhibidors competitius de l’enzim que, a concentracions subinhibitòries, s’uneixen a l’enzim mutant per a formar un complex que l’estabilitza, facilita el seu correcte plegament i posterior transport al lisosoma, resultant en un augment de l’activitat enzimàtica i una reducció del substrat acumulat. A partir de treballs previs en el nostre grup d’investigació en els que s’han obtingut una sèrie d’aminociclitols que es comporten com a inhibidors selectius de la GCase recombinant (imiglucerasa), en aquesta tesi s’ha treballat en el disseny i síntesi de nous potencials inhibidors de la GCase que actuïn com a xaperones farmacològiques, especialment sobre variants neuronopàtiques. Per aquestes raons, els objectius i l’estructuració del treball van ser els següents: 1) Síntesi dels epòxids ciclofelitol i (1R,6S)-epi-ciclofelitol i avaluació com a inhibidors irreversibles de la imiglucerasa i la β–glucosidasa d’Streptomyces sp. wt. 2) Síntesi d’una família d’aminociclitols C7N, relacionats estructuralment amb la Glucosilceramida, el substrat natural de la GCase. 3) Síntesi de noves sèries d’amino- i diaminociclitols, realitzant modificacions en la configuració d’alguns centres de l’anell de ciclitol i en la naturalesa dels substituents. 3) Disseny i síntesi d’una nova família de ciclitols amb estructura bicíclica formats per un anell polihidroxilat de 6 baules fusionat amb una Isourea o una guanidina cíclica de 5 baules. Es va estudiar la importància que té la configuració dels centres en l’activitat inhibidora de la GCase. S’han fet una sèrie d’estudis biològics amb tots els productes sintetitzats. Alguns dels productes van presentar una elevada potència inhibidora de la GCase, tant d’aquest enzim en fibroblasts wild-type com de la imiglucerasa, amb valors de la Ki de l’ordre nanomolar i no van presentar una inhibició destacable sobre altres glicosidases. Després de comprovar que els compostos, que havien resultat ser potents inhibidors de la imiglucerasa, estabilitzen l’activitat d’aquest enzim en condicions de desnaturalització tèrmica, es va estudiar el potencial d’aquests compostos com a xaperones farmacològiques de la GCase amb la col•laboració del Dr. Terry D. Butters. Quan es van tractar els limfoblasts de malalts de Gaucher de les variants N370S o L444P amb alguns dels compostos a concentracions subinhibitòries, es van obtenir augments de l’activitat de la GCase en les cèl•lules tractades respecte a les cèl•lules no tractades. Les concentracions efectives dels compostos en aquest augment són de l’ordre micromolar, nanomolar o fins i tot subnanomolar. Dels resultats obtinguts es pot deduir que, a més de l’alta afinitat per la GCase, alguns compostos presenten la permeabilitat cel•lular, distribució subcel•lular i metabolisme cel•lular adequats per actuar com a xaperones farmacològiques a concentracions molt baixes, de l’ordre nanomolar o inferior.[eng] Gaucher disease (GD) is the most prevalent lysosomal storage disorder caused by a deficiency in the activity of β–glucocerebrosidase (GCase), the lysosomal enzyme responsible for glucosylceramide metabolism into glucose and ceramide. GCase deficiency results in the accumulation of undegraded substrate in the lysosomes of macrophages causing severe symptoms. Approved treatments for GD include enzyme replacement therapy and pharmacological GCase substrate reduction, which are of limited efficacy for disease variants affecting the central nervous system. Recently, a third promising therapeutic option, the pharmacological chaperone therapy, has emerged. This therapy is based on the use of reversible competitive GCase inhibitors that are capable of enhancing its residual hydrolytic activity at sub-inhibitory concentrations by stabilizing the functional form of the misfolded protein and preventing its premature degradation in the endoplasmic reticulum. This improves enzyme trafficking to the lysosome and enhances its hydrolytic activity. The objectives of this thesis were: 1) The synthesis of (i) epoxides cyclophellitol and (1R,6S)- epicyclophellitol, (ii) C7N aminocyclitols derivatives, (iii) new amino- and diaminocyclitol derivatives, and (iv) polyhydroxylated bicyclic Isoureas and guanidines. 2) Evaluation of these compounds as inhibitors of recombinant GCase and other glycosidases. Study the effect of the active compounds on the stabilization of recombinant GCase activity against thermal denaturation, to assess the potential of these compounds as pharmacological chaperones (PC). 3) Evaluation of selected compounds as inhibitors of GCase in wild-type human fibroblasts and exploration of the therapeutical potential as PC in human lymphoblasts derived from Gaucher patients homozygous for N370S or L444P variants. When assayed for effects on GCase activity, some of the compounds displayed selective inhibition of GCase with low micromolar to nanomolar IC50’s in isolated enzyme experiments. Interestingly, the active compounds also behaved as GCase inhibitors in wild-type human fibroblasts at nanomolar concentrations. The potential of these compounds as PC was determined by analyzing their capacity for increasing GCase activity in GD lymphoblasts derived from N370S and L444P variants. Some of the compounds are able to increase the GCase activity at low micromolar to subnanomolar concentrations. These results describe a promising series of potent GCase ligands having the cellular properties required for PC
-
Nous ciclitols com a inhibidors de la glucocerebrosidasa. Aplicació al disseny de xaperones farmacològiques per al tractament de la malaltia de Gaucher
'Edicions de la Universitat de Barcelona', 2011Co-Authors: Trapero Puig AnaAbstract:Els malalts de Gaucher manquen de l’activitat normal de l’enzim lisosomal Glucocerebrosidasa (GCase), una β–glucosidasa que hidrolitza l’enllaç glicosídic entre la glucosa i la ceramida, i són incapaços de metabolitzar la Glucosilceramida, que s’acumula a l’interior dels lisosomes dels macròfags impedint que aquests funcionin correctament. La presència de mutacions en el gen precursor de la GCase provoca un plegament incorrecte de la proteïna en el recicle endoplasmàtic i impedeixen el seu transport al lisosoma on hidrolitza el substrat i, per tant, aquest últim s’acumula en els lisosomes. Per altra banda, la proteïna es degradada en el mateix reticle endoplasmàtic o en l’aparell de Golgi pels proteasomes. Els tractaments actuals per a aquesta malaltia es basen en la inhibició de la producció de substrat utilitzant inhibidors de l’enzim implicat en la seva biosíntesi o en l’augment de l’enzim mitjançant reemplaçament enzimàtic. Durant els últims anys s’han desenvolupat diverses estratègies terapèutiques per a la malaltia de Gaucher. Entre elles, una que ha despertat un gran interès consisteix en el disseny de xaperones farmacològiques, que són inhibidors competitius de l’enzim que, a concentracions subinhibitòries, s’uneixen a l’enzim mutant per a formar un complex que l’estabilitza, facilita el seu correcte plegament i posterior transport al lisosoma, resultant en un augment de l’activitat enzimàtica i una reducció del substrat acumulat. A partir de treballs previs en el nostre grup d’investigació en els que s’han obtingut una sèrie d’aminociclitols que es comporten com a inhibidors selectius de la GCase recombinant (imiglucerasa), en aquesta tesi s’ha treballat en el disseny i síntesi de nous potencials inhibidors de la GCase que actuïn com a xaperones farmacològiques, especialment sobre variants neuronopàtiques. Per aquestes raons, els objectius i l’estructuració del treball van ser els següents: 1) Síntesi dels epòxids ciclofelitol i (1R,6S)-epi-ciclofelitol i avaluació com a inhibidors irreversibles de la imiglucerasa i la β–glucosidasa d’Streptomyces sp. wt. 2) Síntesi d’una família d’aminociclitols C7N, relacionats estructuralment amb la Glucosilceramida, el substrat natural de la GCase. 3) Síntesi de noves sèries d’amino- i diaminociclitols, realitzant modificacions en la configuració d’alguns centres de l’anell de ciclitol i en la naturalesa dels substituents. 3) Disseny i síntesi d’una nova família de ciclitols amb estructura bicíclica formats per un anell polihidroxilat de 6 baules fusionat amb una Isourea o una guanidina cíclica de 5 baules. Es va estudiar la importància que té la configuració dels centres en l’activitat inhibidora de la GCase. S’han fet una sèrie d’estudis biològics amb tots els productes sintetitzats. Alguns dels productes van presentar una elevada potència inhibidora de la GCase, tant d’aquest enzim en fibroblasts wild-type com de la imiglucerasa, amb valors de la Ki de l’ordre nanomolar i no van presentar una inhibició destacable sobre altres glicosidases. Després de comprovar que els compostos, que havien resultat ser potents inhibidors de la imiglucerasa, estabilitzen l’activitat d’aquest enzim en condicions de desnaturalització tèrmica, es va estudiar el potencial d’aquests compostos com a xaperones farmacològiques de la GCase amb la col•laboració del Dr. Terry D. Butters. Quan es van tractar els limfoblasts de malalts de Gaucher de les variants N370S o L444P amb alguns dels compostos a concentracions subinhibitòries, es van obtenir augments de l’activitat de la GCase en les cèl•lules tractades respecte a les cèl•lules no tractades. Les concentracions efectives dels compostos en aquest augment són de l’ordre micromolar, nanomolar o fins i tot subnanomolar. Dels resultats obtinguts es pot deduir que, a més de l’alta afinitat per la GCase, alguns compostos presenten la permeabilitat cel•lular, distribució subcel•lular i metabolisme cel•lular adequats per actuar com a xaperones farmacològiques a concentracions molt baixes, de l’ordre nanomolar o inferior.Gaucher disease (GD) is the most prevalent lysosomal storage disorder caused by a deficiency in the activity of β–glucocerebrosidase (GCase), the lysosomal enzyme responsible for glucosylceramide metabolism into glucose and ceramide. GCase deficiency results in the accumulation of undegraded substrate in the lysosomes of macrophages causing severe symptoms. Approved treatments for GD include enzyme replacement therapy and pharmacological GCase substrate reduction, which are of limited efficacy for disease variants affecting the central nervous system. Recently, a third promising therapeutic option, the pharmacological chaperone therapy, has emerged. This therapy is based on the use of reversible competitive GCase inhibitors that are capable of enhancing its residual hydrolytic activity at sub-inhibitory concentrations by stabilizing the functional form of the misfolded protein and preventing its premature degradation in the endoplasmic reticulum. This improves enzyme trafficking to the lysosome and enhances its hydrolytic activity. The objectives of this thesis were: 1) The synthesis of (i) epoxides cyclophellitol and (1R,6S)- epicyclophellitol, (ii) C7N aminocyclitols derivatives, (iii) new amino- and diaminocyclitol derivatives, and (iv) polyhydroxylated bicyclic Isoureas and guanidines. 2) Evaluation of these compounds as inhibitors of recombinant GCase and other glycosidases. Study the effect of the active compounds on the stabilization of recombinant GCase activity against thermal denaturation, to assess the potential of these compounds as pharmacological chaperones (PC). 3) Evaluation of selected compounds as inhibitors of GCase in wild-type human fibroblasts and exploration of the therapeutical potential as PC in human lymphoblasts derived from Gaucher patients homozygous for N370S or L444P variants. When assayed for effects on GCase activity, some of the compounds displayed selective inhibition of GCase with low micromolar to nanomolar IC50’s in isolated enzyme experiments. Interestingly, the active compounds also behaved as GCase inhibitors in wild-type human fibroblasts at nanomolar concentrations. The potential of these compounds as PC was determined by analyzing their capacity for increasing GCase activity in GD lymphoblasts derived from N370S and L444P variants. Some of the compounds are able to increase the GCase activity at low micromolar to subnanomolar concentrations. These results describe a promising series of potent GCase ligands having the cellular properties required for PC
Xuesong Yin - One of the best experts on this subject based on the ideXlab platform.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
ChemInform, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:The regioselectivity of the acetoxycyclization of N-allylureas to furnish either imidazoles or oxazoles is controlled by choice of the transition-metal catalyst.
-
catalyst controlled amino versus oxy acetoxylation of urea tethered alkenes efficient synthesis of cyclic ureas and Isoureas
Organic Letters, 2015Co-Authors: Weihao Rao, Xuesong Yin, Bingfeng ShiAbstract:A catalyst-controlled vicinal amino- versus oxy-acetoxylation of alkenes with PhI(OAc)2 as the oxidant is described. The divergent synthesis of cyclic ureas and Isoureas was achieved in good yields under mild conditions employing ambident urea nucleophiles. Both terminal and internal alkenes are compatible with this reaction protocol.
Carmen Ortiz Mellet - One of the best experts on this subject based on the ideXlab platform.
-
Probing the Inhibitor versus Chaperone Properties of sp2-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease
MDPI AG, 2018Co-Authors: Teresa Mena-barragán, Alen Sevšek, Roland J. Pieters, Nathaniel I. Martin, Jose Garcia M Fernandez, Isabel M. García-moreno, Tetsuya Okazaki, Eiji Nanba, Katsumi Higaki, Carmen Ortiz MelletAbstract:A series of sp2-iminosugar glycomimetics differing in the reducing or nonreducing character, the configurational pattern (d-gluco or l-ido), the architecture of the glycone skeleton, and the nature of the nonglycone substituent has been synthesized and assayed for their inhibition properties towards commercial glycosidases. On the basis of their affinity and selectivity towards GH1 β-glucosidases, reducing and nonreducing bicyclic derivatives having a hydroxylation profile of structural complementarity with d-glucose and incorporating an N′-octyl-Isourea or -isothiourea segment were selected for further evaluation of their inhibitory/chaperoning potential against human glucocerebrosidase (GCase). The 1-deoxynojirimycin (DNJ)-related nonreducing conjugates behaved as stronger GCase inhibitors than the reducing counterparts and exhibited potent chaperoning capabilities in Gaucher fibroblasts hosting the neuronopathic G188S/G183W mutation, the isothiourea derivative being indeed one of the most efficient chaperone candidates reported up to date (70% activity enhancement at 20 pM). At their optimal concentration, the four selected compounds promoted mutant GCase activity enhancements over 3-fold; yet, the inhibitor/chaperoning balance became unfavorable at much lower concentration for nonreducing as compared to reducing derivatives
-
bicyclic galacto nojirimycin analogues as glycosidase inhibitors effect of structural modifications in their pharmacological chaperone potential towards β glucocerebrosidase
Organic and Biomolecular Chemistry, 2011Co-Authors: Matilde Aguilarmoncayo, Jose Garcia M Fernandez, Isabel M Garciamoreno, Ana Trapero, Meritxell Egidogabas, Amadeu Llebaria, Carmen Ortiz MelletAbstract:A molecular-diversity-oriented approach for the preparation of bicyclic sp2-iminosugar glycomimetics related to nojirimycin and galactonojirimycin is reported. The synthetic strategy takes advantage of the ability of endocyclic pseudoamide-type atoms in five-membered cyclic iso(thio)ureas and guanidines to undergo intramolecular nucleophilic addition to the masked carbonyl group of monosaccharides. The stereochemistry of the resulting hemiaminal stereocenter is governed by the anomeric effect, with a large preference for the axial (pseudo-α) orientation. A library of compounds differing in the stereochemistry at the position equivalent to C-4 in monosaccharides (D-gluco and D-galacto), the heterocyclic core (cyclic Isourea, isothiourea or guanidine) and the nature of the exocyclic nitrogen substituent (apolar, polar, linear or branched) has been thus prepared and the glycosidase inhibitory activity evaluated against commercial glycosidases. Compounds bearing lipophilic substituents behaved as potent and very selective inhibitors of β-glucosidases. They further proved to be good competitive inhibitors of the recombinant human β-glucocerebrosidase (imiglucerase) used in enzyme replacement therapy (ERT) for Gaucher disease. The potential of these compounds as pharmacological chaperones was assessed by measuring their ability to inhibit thermal-induced denaturation of the enzyme in comparison with N-nonyl-1-deoxynojirimycin (NNDNJ). The results indicated that amphiphilic sp2-iminosugars within this series are more efficient than NNDNJ at stabilizing β-glucocerebrosidase and have a strong potential in pharmacological chaperone (PC) and ERT-PC combined therapies.
-
synthesis and evaluation of Isourea type glycomimetics related to the indolizidine and trehazolin glycosidase inhibitor families
Journal of Organic Chemistry, 2003Co-Authors: Isabel M Garciamoreno, Carmen Ortiz Mellet, Paula Diazperez, Jose Garcia M FernandezAbstract:A practical synthesis of reducing Isourea-derived azasugar glycomimetics related to the indolizidine and trehazolin glycosidase inhibitor families with different pKa values is disclosed. The polyhydroxylated bicyclic system was built from readily accessible hexofuranose derivatives through a synthetic scheme that involves the preparation of a 5-deoxy-5-carbodiimido adduct by triphenylphosphine-mediated tandem Staudinger−aza-Wittig-type coupling of azide and isothiocyanate precursors, intramolecular cyclization of a transient vic-hydroxycarbodiimide derivative, and nucleophilic addition of the endocyclic nitrogen atom of the generated 2-amino-2-oxazoline intermediate, with a pseudo-C-nucleoside structure, to the masked aldehyde group of the monosaccharide. The last step is pH-dependent so that the final compounds can pivot between the furanose and the 2-oxaindolizidine forms. Nevertheless, the indolizidine tautomer having the R configuration at the aminoacetalic center, fitting the anomeric effect, was the...
